Navigation Links
ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
Date:8/28/2012

SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012 at 2:25 p.m. Eastern time, in the Starlight Center Salon at The Waldorf Astoria hotel in New York City.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function which is compromised in a wide range of serious and life-threatening diseases and conditions.  The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

(Logo: http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a)


'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ADVENTRX Announces Appointment Of Chief Medical Officer
2. ADVENTRX Pharmaceuticals to Present at 1st Annual Sickle Cell Disease Therapeutics Conference
3. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
4. ADVENTRX Pharmaceuticals To Present At The OneMedForum New York 2012 Emerging Company Finance Conference On July 12
5. ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product
6. ADVENTRX Pharmaceuticals To Present At 2012 BIO International Convention Business Forum
7. Esperance Pharmaceuticals Announces Completion of Run-in Enrollment of Phase 2 Study of EP-100 Plus Paclitaxel in Advanced Ovarian Cancer
8. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
9. Alder Biopharmaceuticals Receives $3.5 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2 Clinical Trial of ALD518/BMS-945429 in Crohns Disease
10. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
11. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
(Date:6/24/2016)... Palm City, FL (PRWEB) , ... June 24, 2016 , ... ... and inflammation common after venous procedures, dermaka cream can be incorporated into the post-surgical ... peels, and minor surgical procedures. , dermaka cream is very effective for bruising ...
Breaking Medicine News(10 mins):